Bookmark and Share

Alonso  Heredia
 

Alonso Heredia Ph.D.

Academic Title: Assistant Professor
Primary Appointment: Medicine
aheredia2@ihv.umaryland.edu
Location: 725 W. Lombard Street N549

Personal History:

Positions and Employment

1995 -1997: Postdoctoral training. Lab Molecular Virology. Food and Drug Administration. Bethesda
1997 - 2008: Research Associate, Clinical Research Div, IHV, Univ of Maryland School of Medicine
2008 – present: Assistant Professor, Clinical Research Div, IHV, Univ of Maryland School of Medicine


Publications:

Recent Publications

Margolis D, Heredia A, Gaywee J, Oldach D, Drusano G, Redfield R. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity.  J AIDS and Human Retrovirology 1999, 21: 362-370

Heredia A, Margolis D, Oldach D, Hazen R, Le N, Redfield R. Abacavir  in combination with the Inosine Monophosphate Dehydrogenase (IMPDH)-Inhibitor Mycophenolic Acid is active against multidrug-resistant  HIV-1. J AIDS and Human Retrovirology 1999, 22: 406-407

Heredia A, Davis C, Redfield R. The synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogs combined with a natural product, resveratrol. J AIDS and Human Retrovirology 2000, 25: 246-255

Heredia A, Davis C, Le N, Dominique JK, Redfield RR. Differential HIV-suppressive activity of RT inhibitors in resting and activated peripheral blood lymphocytes: implications for therapy. J Human Virology 2001, 4: 113-122.

Heredia A, Davis C, Amoroso A, Dominique JK, Le N, Klingebiel E, Reardon E, Zella D, Redfield RR. Induction of G1 cycle arrest in T lymphocytes results in increased extracellular levels of beta-chemokines: a strategy to inhibit R5 HIV-1. Proc Natl Acad Sci USA 2003, 100: 4179-4184.

Heredia A, Amoroso A, Davis C, Le N, Reardon E, Dominique JK, Klingebiel E, Gallo RC, Redfield RR. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci USA 2003, 100: 10411-10416.

Naicker KP, Li H, Heredia A, Song H, Wang LX. Design and synthesis of alpha Gal-conjugated peptide T20 as novel antiviral agent for HIV-immunotargeting. Org Biomol Chem. 2004, 7: 660-664.

Wang LX, Heredia A, Song H, Zhang Z, Yu B, Davis C, Redfield R. Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti-HIV activity. J Pharm Sci. 2004, 10: 2448-2457.

Li H, Song H, Heredia A, Le N, Redfield R, Lewis G, Wang LX. Synthetic bivalent CD4-mimetic miniproteins show enhanced anti-HIV activity over the monovalent miniprotein. Bioconjug Chem. 2004, 15: 783-789.

Wang J, Le N, Heredia A, Song H, Redfield R, Wang LX. Modification and structure-activity  relationship of a small molecule HIV-1 inhibitor targeting the viral envelope glycoprotein gp120. Org Biomol Chem 2005, 3: 1781-1786.

Heredia A, Davis C, Amoroso A, Taylor G, Le N, Bamba D, Redfield R. In vitro suppression of latent HIV-1 activation by vitamin E: potential clinical implications. AIDS 2005, 19: 836-837.

Heredia A, Davis c, Bamba D, Le N, Gwarzo M, Sadowska M, Gallo R, Redfield R. Indirubin-3’-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication. AIDS 2005, 19: 2087-2095.

Sajadi M, Heredia A, Le N, Constantine N, Redfield R. HIV-1 natural viral suppressors: control of viral replication in the absence of therapy. AIDS 2007, 21: 517-519.

Heredia A, Gilliam B, Devico A, Le N, Bamba D, Flinko R, Lewis G, Gallo RC, Redfield RR. CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1. AIDS. 2007, 21:1317-1322.

Heredia A, Gilliam B, Latinovic O, Le N, Bamba D, Devico A, Melikyan GB, Gallo RC, Redfield RR. Rapamycin reduces CCR5 density levels on CD4 T cells and this effect results in potentiation of Enfuvirtide (T-20) against R5 HIV-1 in vitro. Antimicrob Agents Chemother. 2007, 51:2482-2496.

Gilliam B, Heredia A, DeVico A, Le N, Bamba D, Bryant J, Pauza D, Redfield R. Rapamycin reduces CCR5 m-RNA levels in macaques: Potential applications in HIV-1 prevention and treatment. AIDS 2007, 21:2108-2110.

Taylor B, Foulke J, Flinko R, Heredia A, Devico A, Reitz M. An Alteration of HIV gp41 leading to reduced CCR5 dependence and CD4 independence. J Virol 2008, 82(11): 5460-5471.

Heredia A, Latinovic O, Gallo R, Melikyan G, Reitz M, Le N, Redfield R. Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proc Natl Acad Sci USA 2008, 105: 20476-20481.

Huang W, Groothuys S, Heredia A, Kuijpers BH, Rutjes FP, van Delft FL, Wang LX. Enzymatic glycosylation of triazole-linked GlcNAc/Glc-peptides: synthesis, stability and anti-HIV activity of triazole-linked HIV-1 gp41 glycopeptide C34 analogues. Chembiochem. 2009, 10(7): 1234-1242

Latinovic O, Heredia A, Gallo RC, Reitz M, Le N, Redfield RR.  Rapamycin Enhances Aplaviroc Anti-HIV Activity:  Implications for the Clinical Development of Novel CCR5 Antagonists. Antiviral Research 2009, 83: 86-89.

Latinovic O, Kuruppu J, Davis C, Heredia A. Pharmacotherapy of HIV-1 infection: focus on Maraviroc. Clin Med Ther (submitted).